These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36583779)

  • 1. Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?
    Lima T; Perpétuo L; Henrique R; Fardilha M; Leite-Moreira A; Bastos J; Vitorino R
    Mol Biol Rep; 2023 Mar; 50(3):2763-2778. PubMed ID: 36583779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).
    Dong R; Zhang M; Hu Q; Zheng S; Soh A; Zheng Y; Yuan H
    Int J Mol Med; 2018 Feb; 41(2):599-614. PubMed ID: 29207027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases.
    Hara A; Niwa M; Noguchi K; Kanayama T; Niwa A; Matsuo M; Hatano Y; Tomita H
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32138174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
    Schulz H; Schmoeckel E; Kuhn C; Hofmann S; Mayr D; Mahner S; Jeschke U
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.
    Caputo S; Grioni M; Brambillasca CS; Monno A; Brevi A; Freschi M; Piras IS; Elia AR; Pieri V; Baccega T; Lombardo A; Galli R; Briganti A; Doglioni C; Jachetti E; Bellone M
    Front Immunol; 2020; 11():1820. PubMed ID: 33013832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner.
    Kim SJ; Chun KH
    BMB Rep; 2020 Apr; 53(4):173-180. PubMed ID: 32172730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 in Cardiovascular Diseases.
    Blanda V; Bracale UM; Di Taranto MD; Fortunato G
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Mutation in the Carbohydrate Recognition Domain Drives a Phenotypic Switch in the Role of Galectin-7 in Prostate Cancer.
    Labrie M; Vladoiu M; Leclerc BG; Grosset AA; Gaboury L; Stagg J; St-Pierre Y
    PLoS One; 2015; 10(7):e0131307. PubMed ID: 26168167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
    Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
    Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of galectin-3 in autoimmune and non-autoimmune nephropathies.
    Saccon F; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
    Autoimmun Rev; 2017 Jan; 16(1):34-47. PubMed ID: 27666815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the pathophysiologic role of galectin-3 in chronically injured liver.
    Ezhilarasan D
    J Cell Physiol; 2023 Apr; 238(4):673-686. PubMed ID: 36745560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population.
    Aggarwal S; Sharma SC; Das SN
    Clin Chim Acta; 2015 Mar; 442():13-21. PubMed ID: 25578395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3 in cancer.
    Song L; Tang JW; Owusu L; Sun MZ; Wu J; Zhang J
    Clin Chim Acta; 2014 Apr; 431():185-91. PubMed ID: 24530298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.
    van den Brûle FA; Waltregny D; Liu FT; Castronovo V
    Int J Cancer; 2000 Jul; 89(4):361-7. PubMed ID: 10956411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives.
    Bartolazzi A; Sciacchitano S; D'Alessandria C
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galectin-9 as a biomarker of disease severity.
    Moar P; Tandon R
    Cell Immunol; 2021 Mar; 361():104287. PubMed ID: 33494007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.
    Gentilini LD; Jaworski FM; Tiraboschi C; Pérez IG; Kotler ML; Chauchereau A; Laderach DJ; Compagno D
    Oncotarget; 2017 Jul; 8(27):44654-44668. PubMed ID: 28591719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectin-3 in angiogenesis and metastasis.
    Funasaka T; Raz A; Nangia-Makker P
    Glycobiology; 2014 Oct; 24(10):886-91. PubMed ID: 25138305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of Galectin-3 in Acute Myocardial Infarction.
    Li M; Yuan Y; Guo K; Lao Y; Huang X; Feng L
    Am J Cardiovasc Drugs; 2020 Aug; 20(4):333-342. PubMed ID: 31784887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
    Grosset AA; Labrie M; Vladoiu MC; Yousef EM; Gaboury L; St-Pierre Y
    Oncotarget; 2016 Apr; 7(14):18183-203. PubMed ID: 26933916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.